

***Global health Security Conference Sydney June 2024 –  
Wednesday 19<sup>th</sup> June – 7:00 – 8:00am***

***GARDP & SECURE SPONSORED BREAKFAST***

***Product Development Partners ROUND TABLE***

***CONCEPT NOTE***

### **Introduction**

Antimicrobial resistance (AMR) is a major theme of the 2024 Global Health Security Conference. Access to appropriate antibiotic treatments can be lifesaving. Unfortunately, not only is the pipeline for new antibacterial drugs to address the growing burden of antimicrobial resistance (AMR) inadequate, even after antibiotics are successfully developed, they are not necessarily accessible. The market for new antibiotics to treat drug-resistant infections is nascent, particularly in low-resource settings. As new treatments to tackle AMR become available, access is limited or delayed by several market hurdles including low and uncertain demand, high-prices and concerns around appropriate use. For small and unpredictable but growing markets, it is important to carefully balance supply and demand, support sustainable and affordable access, and incentivize appropriate use through market interventions such as coordinated procurement and stockpiling.

**This Round Table discussion hosted by GARDP and SECURE will gather experts to share their experiences in market shaping, describe how market shaping interventions in other disease areas may be applied to AMR, and discuss potential interventions that may improve sustainable, reliable, and affordable access to critical antibiotics.**

### **GARDP & SECURE**

Global Antibiotic R&D Partnership (GARDP) ([www.gardp.org](http://www.gardp.org)) is a not-for-profit organisation that is working with partners in LMICs. GARDP is working to deliver new treatments for resistant infections to LMICs, including cefiderocol for complicated urinary tract infections (cUTIs), cefipemantaniborbactam for hospital-acquired bacterial pneumonia and zoliflodacin for the treatment of *Neisseria gonorrhoea*. GARDP has managed clinical trials in LMICs to support the registration of these new antibiotics. Our work includes facilitating access in LMICs where access to antibiotics with activity against resistant bacteria is usually delayed by more than a decade.

SECURE is an innovative initiative being developed by World Health Organization (WHO) and the Global Antibiotic Research and Development Partnership (GARDP) to improve access to both existing and new antibiotics. SECURE will increase access to a portfolio of quality-assured antibiotics in a sustainable, equitable and appropriate way. It will improve appropriate access to both existing and new antibiotics.

### **GHSC Breakfast**

The objective of the breakfast on Wednesday 19<sup>th</sup> June morning is to facilitate an exchange of information among PDPs focused on improving access to medicines. During the roundtable, speakers will have the opportunity to share knowledge and examples of market-based approaches to catalysing

access to healthcare tools across the value chain. This will include examples showcasing PDP's role in supporting local manufacturing, product registration, navigating WHO PQ/SRA approval, facilitating product introduction, and managing large scale market shaping projects that utilise interventions such as demand forecasting/aggregation, volume guarantees, catalytic subsidies and pooled procurement.

The breakfast will be interactive, a round table format, and will feature seated panellists rather than presentations from a lectern. The proposed panellists are;

- Dr. Jennifer Cohn, Director for Global Access, GARDP (Panel Moderator)
- Dr. Kim Faure, SECURE Project Lead
- Justin McBeath, CEO, Innovative Vector Control Consortium (IVCC) (TBC)
- Adam Aspinall, Senior Director, Access & Product Management, Medicines for Malaria Venture (MMV)
- Mel Spigelman President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance)
- Mark Sullivan founder and managing director, Medicines Development for Global health (MDGH)

Key discussion points at the breakfast would include;

- Case studies demonstrating approaches from other diseases/products to bring health products facing access hurdles to markets
- Market shaping approaches that shape the sustainable entry of products which are low volume, high price and erratic demand.
- The SECURE initiative and mechanisms to address these access challenges.

The breakfast could include the announcement by a Minister for Health which has chosen to participate in a SECURE pilot or demonstration project in their country.

### **Outline for the Session:**

#### **Moderator: Jennifer to introduce the Round Table discussion**

##### **Intro**

1. 10 min Introduction on SECURE and GARDP – Kim Faure and Jennifer Cohn

##### **Panel discussion**

2. 30 min - Curated discussion with panellists on how AMR may learn from other disease area interventions in relation to improving access to critical medicines
3. 10 min Q&A session (with moderator and panellists)– from audience questions
4. 3 min – last words – each panellist has 1 min & concluding statements
5. Closing remarks by moderator

Curated discussion: Questions for panellists – to be discussed and shaped by panellists themselves

1. Reflect on your experiences in bringing products to markets, including supporting local manufacturing, use of forecasting models, country subsidies and volume guarantees in the past.
2. What lessons have you learnt that might apply to initiatives in the AMR space.